Answers are grounded in this paper and cite their sources.
The authors describe a novel case of a 48-year-old male with bilateral diabetic macular edema (DME) who underwent intravitreal injection (IVI) of brolucizumab in the left eye. At four weeks, the patient demonstrated a bilateral response by way of improvement in the best-corrected visual acuity (BCVA) and reduction in the central macular thickness (CMT) in both eyes. Further studies on the ocular and systemic assays of the brolucizumab molecule are warranted to evaluate its systemic escape and to better understand the pharmacokinetics behind the bilateral effect.
No takes yet. Share an insight, caveat, or question.
Chakraborty et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: